xpert Comments:mce-anchor
Column 1 Column 2 0 Kevin DeGeeter, Ladenburg Thalmann (5/10/16)"Mesoblast Ltd. announced 3Q16 results in line with our forecast and provided several important updates including: 1) agreement with FDA regarding Phase III study design for its MPC-06-ID program for treatment of chronic lower back pain, 2) confirmation of positive interim review by the DSMB for the Phase III heart failure program, and 3) positive enrollment update on U.S. pediatric GvHD Phase III program with potential interim results late in 3Q16. . .the company is now well positioned to potentially conclude partnering discussions for MPC-06-ID in the coming months. . .we reiterate our Buy rating and $17.25 price target." 1 Jason Kolbert, Maxim Group (5/10/16)"Mesoblast Ltd. spent $22M in the quarter and closed the period with $100M in cash. . .the company highlighted the lower cash burn, down 25% vs. the same period last year. . .the heart failure trial is recruiting well in North America and is expected to expand more aggressively in the EU, as sites there are being opened."
Some are positive !!
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |